A study involving hospitalized adults today in JAMA Network Open finds that severe COVID-19 negatively affects brain health, but no more so than pneumonia, heart attack, or other critical illnesses.
Due to its rapid growth and potential to add to the respiratory virus burden in Northern Hemisphere countries, the World Health Organization (WHO) today designated JN.1, part of the BA.2.86 SARS-CoV-2 lineage, as its own variant of interest.
Over the past month, the proportion of JN.1 viruses has rapidly increased, rising from 3.3% in early November to 27.1% by early December. Countries reporting the highest proportions include France, the United States, Singapore, Canada, and the United Kingdom.